Vonoprazan Fumarate
【Chemical Name】Vonoprazan Fumarate
【Original】Takeda & Otsuka
【Time to market】2014.12.26
【Patents expire】2026.8.29
【Use】Oral Vonoprazan tablets containing 10 or 20 mg each are used to treat gastric ulcer, duodenal ulcer and reflux esophagitis.
Vonoprazan Fumarate
一、Product Overview
Vonoprazan Fumarate was jointly developed by Takeda and Otsuka for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. On December 26, 2014, Vonoprazan Fumarate was approved for market by PMDA, and the compound patent expired on August 29, 2026.
二、Main products
Description | Structural Formula | CAS No. | Category |
Vonoprazan Fumarate |  | 1260141-27-2 | API |
3-Pyridinesulfonylchloride |  | 16133-25-8 | intermediates |
5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde |  | 881674-56-2 | intermediates |
5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-carboxaldehyde |  | 881677-11-8 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.